Health insurers and pharmacy benefit managers (PBMs) are hoping recent mergers and their growing market clout will help them win steeper drug discounts in their ongoing war with the pharmaceutical industry over specialty drug pricing.
At the center of the huge U.S. drug research enterprise sit some of its lowest-paid workers, who do the data-entry scut work that holds most research projects together. Unfortunately, they often must juggle their tasks between separate data systems.
Data Points for the week of Aug. 3, 2015, covered the following topics: Veterans, antibiotic use, ultrasounds, drug prices, behavioral health
New proposed federal rules released this week aim to track how production and facility problems lead to a shortage of certain drugs.
Dr. Lorraine Fitzpatrick is the new CMO at Radius Health, a biopharmaceutical company developing therapeutics for patients with advanced osteoporosis and other serious endocrine-mediated diseases.
Sales of Sovaldi and Harvoni accounted for 60% of Gilead's revenue for the second quarter of 2015. The drugs have treated more than 180,000 hepatitis C patients in the U.S. and Europe since the beginning of the year, according to the company.
Gilead Sciences on Tuesday reported second-quarter earnings of $4.49 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.92. Earnings, adjusted for costs related to mergers and acquisitions and stock option expense, came to $3.15 per share.
Pharmaceutical giant Pfizer on Tuesday reported continuing declines in sales and earnings as it girds for the loss of patent protection in Europe and Japan of Enbrel, its rheumatoid arthritis drug.
Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan.
Israel's Teva Pharmaceutical Industries said Monday it is purchasing Dublin-based Allergan's generic pharmaceuticals business for $40.5 billion, in what analysts called the largest-ever acquisition by an Israeli company.
British pharmaceutical giant AstraZeneca plans to sell its thyroid cancer drug Caprelsa to Cambridge, Mass.-based Genzyme in a deal valued at $300 million. It's part of the company's strategy to move away from rare disease offerings and focus on key treatments.
The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. But the drug's $14,600-a-year price tag is certain to escalate debate about the cost of breakthrough drugs.